Human tumor antigens for cancer vaccine development

Immunological Reviews

Volumn 170, Issue , 1999, Pages 85-100

  Wang, Rong Fu ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; DIFFERENTIATION ANTIGEN; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; CANCER; CLINICAL TRIAL; HUMAN; IMMUNE RESPONSE; INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION; VACCINE PRODUCTION;

ADOPTIVE TRANSFER; AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; CANCER VACCINES; EPITOPES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOSOMES; MOLECULAR SEQUENCE DATA; NEOPLASMS; PEPTIDES; T-LYMPHOCYTES;

EID: 0032880649     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01331.x     Document Type: Review

References (151)

1. 1. Rosenberg SA, et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N Engl J Med 1988;319:1676-1680.
2. 2. Rosenberg SA. The immunotherapy and gene therapy of cancer. J Clin Oncol 1992;10:180-199.
3. 3. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233:1318-1321.
4. 4. Kast WM, et al. Eradication of adenovirus E1-induced tumors by E1A specific cytotoxic T lymphocytes. Cell 1989;59:603-614.
5. 5. Greenbeerg PD, Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991;49:281-355.
6. +2 lymphocytes. J Exp Med 1981;154:952-963.
7. + helper T cells are required for resistance to a highly metastatic murine tumor. Eur J Immunol 1987;17:1863-1866.
8. 8. Romerdahl CA, Kripke ML. Role of helper T-lymphocytes in rejection of UV-induced murine skin cancers. Cancer Res 1988;48:2325-2328.
9. + T cells in the antitumor immune response. J Exp Med 1998;188:2357-2368.
10. 10. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998;187:693-702.
11. 11. Rosenberg SA, et al. Immunologic and therapeutic evaluation of a synthetic tumor-associated peptide vaccine for the treatment of patients with metastitic melanoma. Nat Med 1998;4:321-327.
12. 12. Rosenberg SA, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998;90:1894-1900.
13. 13. Van Den Eynde B, Lethë B, Van Pel A, De Plaen E, Boon T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med 1991;173:1373-1384.
14. 14. Brichard V, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-495.
15. 15. Coulie PG, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
16. 16. Wang R-F, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 1995;181:799-804.
17. 17. Kawakami Y, et al. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J Immunother (In press).
18. 18. Wang R.-F, Wang X, Johnston SL, Zeng G, Robbins PF, Rosenberg SA. Development of a retrovirus-based complementary DNA expression system for the cloning of tumor antigens. Cancer Res 1998;58:3519-3525.
19. 19. Cox AL, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994;264:716-719.
20. 20. Blake J, Johnston JV, Hellstrom KE, Marqardt H, Chen L. Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes. J Exp Med 1996;184:121-130.
21. 21. Cheever MA, et al. Immunity to oncogenic proteins. Immunol Rev 1995;145:33-59.
22. 22. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995;181:2109-2117.
23. 23. Sahin U, Tureci O, Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol 1997;9:709-716.
24. 24. Old LJ, Chen YT. New paths in human cancer serology. J Exp Med 1998;187:1163-1167.
25. 25. Sahin U, et al. Human neoplasms elicit multiple immune responses in the autologous host. Proc Natl Acad Sci USA 1995;92:11810-11813.
26. 26. Chen YT, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997;94:1914-1918.
27. 27. Tureci O, et al. The SSX-2 gene, which is involved in the t(X; 18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL 40. Cancer Res 1996;56:4766-4772.
28. 28. Tureci O, Sahin U, Zwick C, Koslowski M, Seitz G, Pfreundschuh M. Identification of a meiosis-specific protein as a member of the class of cancer-testis antigens. Proc Natl Acad Sci USA 1998;95:5211-5216.
29. 29. Chen YT, et al. Identification of multiple cancer/testis antigens by allogencic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA 1998;95:6919-6923.
30. 30. Van der Bruggen P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-1647.
31. 31. Jager E, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998;187:265-270.
32. 32. Wang R-F, Johnston SL, Zeng G, Schwartzentruber DJ, Rosenberg SA. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol 1998;161:3596-3606.
33. 33. Jung S, Schluesener HJ. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 1991;173:273-276.
34. 34. Skipper J, Stauss HJ. Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein. J Exp Med 1993;177:1493-1498.
35. 35. Celis E, et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 1994;91:2105-2109.
36. + tumors. Cancer Res 1998;58:4902-4908.
37. 37. Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995;41:178-228.
38. 38. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 1995;92:11993-11997.
39. 39. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman A. Tolerance to p53 by A2.I-restricted cytotoxic T lymphocytes. J Exp Med 1997;185:833-841.
40. 40. Traversari C, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453-1457.
41. 41. Van der Bruggen P, et al. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing Cw1601. Eur J Immunol 1994;24:2134-2140.
42. 42. Gaugler B, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994;179:921-930.
43. 43. Van der Bruggen P, et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994;24:3038-3043.
44. 44. Herman J, et al. A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Immunogenetics 1996;43:377-383.
45. 45. Boel P, et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995;2:167-175.
46. 46. Van Den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995;182:689-698.
47. 47. Wang R-F, Appella E, Kawakami Y, Kang X, Rosenberg SA. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996;184:2207-2216.
48. 48. Lee L, et al. NY-ESO 1 may be a potential target for lung cancer immunotherapy. Cancer J Sci Am 1998;5:20-25.
49. 49. Stockert E, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-1354.
50. 50. Gaugler B, et al. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics 1996;44:323-330.
51. 51. Richards JM, Mehta N, Ramming K, Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992;10:1338-1343.
52. 52. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targeted for cancer immunotherapy. J Immunother 1996;19:81-84.
53. 53. Weber, LW et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 1998;102:1258-1264.
54. + T lymphocytes. Proc Natl Acad Sci USA 1999;96:2982-2987.
55. 55. Bouchard B, Fuller BB, Vijayasaradhi S, Houghton AN. Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA. J Exp Med 1989;169:2029-2042.
56. 56. Wolfel T, et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994;24:759-764.
57. 57. Robbins PF, El-Gamil M, Kawakami Y, Stevens E, Yannelli J, Rosenberg SA. Recognition of tyrosinase by tumor infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 1994;54:3124-3126.
58. 58. Kang X-Q, et al. Identification of a tyrosinase epitope reocognized by HLA A24 restricted tumor-infiltrating lymphocytes. J Immunol 1995;155:1343-1348.
59. 59. Brichard VG, et al. A tyrosinase nonpeptide presented by HLA B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur J Immunol 1996;26:224-230.
60. 60. Skipper JC, et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996;183:527-534.
61. 61. Kawakami Y, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-3519.
62. 62. Kawakami Y, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-352.
63. 63. Sensi M, et al. Cytotoxic T lymphocyte clones from different patients display limited T-cell receptors variable gene usage in HLA-A2 restricted recognition of Melan/Mart-1 melanoma antigen. Proc Natl Acad Sci USA 1995;92:5674-5678.
64. 64. Valmori D, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 1998;160:1750-1758.
65. 65. Schneider J, Brichard V, Boon T, Meyer zum Buschenfelde KH, Wolfel T. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA B45.1 and HLA-A2.1. Int J Cancer 1998;75:451-458.
66. 66. Loftus DJ, et al. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1 27-35. J Exp Med 1996;184:647-657.
67. 67. Kawakami Y, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-3968.
68. 68. Adema GJ, et al. Melanocyte lineage-specific antigens recognized by monoclonal antibodies NK1-beteb, HMB-50, and HMB 45 are encoded by a single cDNA. Am J Pathol 1993;143:1579-1585.
69. 69. Bakker ABH, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanocyte-derived tumor-infiltrating lymphocytes. J Exp Med 1994;179:1005-1009.
70. 70. Kawakami Y, et al. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458-6462.
71. 71. Bakker A, et al. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1 restricted anti-melanoma CTL line. Int J Cancer 1995;62:97-102.
72. 72. Kawakami Y, et al. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol 1998;161:6985-6992.
73. 73. Skipper JCA, et al. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. J Immunol 1996;157:5027-5033.
74. 74. Mattes MJ, Thomson TM, Old LJ, Lloyd KO. A pigmentation-associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum. Int J Cancer 1983;32:717-721.
75. 75. Thomson TM, Mattes JM, Roux L, Old LJ, Lloyd KO. Pigmentation-associated glycoprotein of human melanoma and melanocytes: definition with a mouse monoclonal antibody. J Invest Dermat 1985;85:169-174.
76. 76. Thomson TM, Real FX, Murakami S, Cordon-Cardo C, Old LJ, Houghton AN. Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. J Invest Dermat 1988;90:459-466.
77. 77. Jimenez-Cervantes C, et al. A new enzymatic function in the melanogenic pathway. J Biol Chem 1994;269:17993-18001.
78. 78. Bloom MB, et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997;185:453-460.
79. 79. Zeh HJ, 3rd, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999;162:989-994.
80. 80. Sidney J, Grey HM, Kubo RT, Sette A. Practical, biochemical and evolutinary implications of the discovery of HLA class I supermotifs. Immunol Today 1996;17:261-266.
81. 81. Sidney J, et al. Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide binding repertoires of common HLA molecules. Hum Immunol 1996;45:79-93.
82. 82. Wang R-F, Johnston S, Southwood S, Sette A, Rosenberg SA. Recognition of an antigenic peptide derived from TRP-2 by cytotoxic T lymphocytes in the context of HLA-A31 and -A33. J Immunol 1998;160:890-897.
83. 83. Parkhurst MR, Fitzgerald EB, Southwood S, Sette A, Rosenberg SA, Kawakami Y. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res 1998;58:4895-4901.
84. 84. Van Elsas A, et al. Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201. Int J Cancer 1995;61:389-396.
85. 85. Houbiers JGA, et al. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 1993;23:2072-2077.
86. 86. Nijman HW, et al. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol 1993;23:1215-1219.
87. 87. Nijman HW, van der Burg SH, Vierboom MP, Houbiers JG, Kast WM, Melief CJ. p53, a potential target for tumor-directed T cells. Immunol Lett 1994;40:171-178.
88. 88. Coulie PG, et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 1995;92:7976-7980.
89. 89. Wolfel T, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-1284.
90. 90. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995;9:1149-1163.
91. 91. Robbins PF, et al. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996;183:1185-1192.
92. 92. Grunwald GB. The structural and functional analysis of cadherin calcium-dependent cell adhesion molecules. Curr Opin Cell Biol 1993;5:797-805.
93. 93. Hoschuetzky H, Aberle H, Kemler R. β-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol 1994;127:1375-1380.
94. 94. Becker KF, et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 1994;54:3845-3852.
95. 95. Kawanishi J, Kato J, Sasaki K, Fujii S, Watanabe M, Niitsu Y. Loss of E-cadherin-dependent cell-cell adhesion due to mutation of the β-catenin gene in a human cancer cell line, HSC-39. Mol Cell Biol 1995;15:1175-1181.
96. 96. Korinek V, et al. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC-/-colon carcinoma. Science 1997;275:1784-1787.
97. 97. Morin PJ, et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275:1787-1790.
98. 98. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of beta catenin by genetic defects in melanoma cell lines. Science 1997;275:1790-1792.
99. 99. Mandruzzato S, Brasseur F, Andry G, Boon T, van der Bruggen P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 1997;186:785-793.
100. 100. Ioannides CG, Fisk B, Pollack MS, Frazier ML, Wharton JT, Freedman RS. Cytotoxic T-cell clones isolated from ovarian tumour infiltrating lymphocytes recognize common determinants on nonovarian tumour clones. Scand J Immunol 1993;37:413-424.
101. 101. Yoshino I, Peoples GE, Geoedegebauure PS, Mazizrz R, Eberlein TJ. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J Immunol 1994;152:2393-2400.
102. 102. Disis ML, et al. Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994;54:16-20.
103. 103. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995;92:432-436.
104. 104. Linehan DC, Goedegebuure PS, Peoples GE, Rogers SO, Eberlein TJ. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J Immunol 1995;155:4486-4491.
105. 105. Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 1993;151:3693-3703.
106. 106. Magarian-Blander J, Domenech N, Finn OJ. Specific and effective T-cell recognition of cells transfected with a truncated human mucin cDNA. Ann N Y Acad Sci 1993;690:231-243.
107. 107. Finn OJ, et al. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 1995;145:61-89.
108. 108. Apostolopoulos V, Karanikas V, Haurum JS, McKenzie IF. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J Immunol 1997;159:5211-5218.
109. 109. Domenech N, Henderson RA, Finn OJ. Identification of an HLA-A1 I-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 1995;155:4766-4774.
110. 110. Wang R-F, Parkhurst MR, Kawakami Y, Robbins PF, Rosenberg SA. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med 1996;183:1131-1140.
111. 111. Spiropoulou CF, Nichol ST. A small highly basic protein is encoded in overlapping frame within the P gene of vesicular stomatitis virus. J Virol 1993;67:3103-3110.
112. 112. Schwartz S, Felber BK, Pavlakis GN. Mechanism of translation of monocistronic and multicistronic human immunodeficiency virus type 1 mRNAs. Mol Cell Biol 1992;12:207-219.
113. 113. Lethe B, et al. LAGE-1, a new gene with tumor specificity. Int J Cancer 1998;76:903-908.
114. 114. Arrnoudse CA, Van Den Doel PB, Heemskerk B, Schrier PI. Interleukin-2 induced melanoma-specific T cells recognize CAMEL, an unexpected translational product of LAGE. Int J Cancer (In press).
115. 115. Mayrand SM, Schwarz DA, Green WR. An alternative translational reading frame encodes an immunodominant retroviral CTL determinant expressed by an immunodeficiency-causing retrovirus. J Immunol 1998;160:39-50.
116. 116. Mayrand SM, Green WR. Non-traditionally derived CTL epitopes: exceptions that prove the rules? Immunol Today 1998;19:551-556.
117. 117. Guilloux Y, et al. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med 1996;183:1173-1183.
118. 118. Robbins P, El-Gamil M, Li YF, Fitzgerald E, Kawakami Y, Rosenberg SA. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. J Immunol 1997;159:303-308.
119. 119. Lupetti R, et al. Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. J Exp Med 1998;188:1005-1016.
120. 120. Ostrand-Rosenberg S. Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr Opin Immunol 1994;6:722-727.
121. + T cell responses in antitumor immunity. Curr Opin Immunol 1998;10:588-594.
122. 122. Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T Cells and their role in antitumor immune responses. J Exp Med 1999;189:753-756.
123. + T cells. Crit Rev Immunol 1998;18:569-594.
124. 124. Tisch, R, and H. McDevitt. Insulin-dependent diabetes mellitus. Cell 1996;85:291-297.
125. + T-cell subsets in autoimmunity. Curr Opin Immunol 1997;9:872-883.
126. 126. Bona CA, Casares S, Brumeanu TD, Towards development of T-cell vaccines. Immunol Today 1998;19:126-133.
127. 127. Riddell SR, Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 1995;13:545-586.
128. 128. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998;188:2199-2204.
129. + T lymphocytes. J Interferon Cytokine Res 1995;15:739-746.
130. + T lymphocytes infiltrating human breast cancer recognize autologous tumor in an MHC-class II restricted fashion. Cancer Immunol Immunother 1995;40:1-9.
131. + T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. J Immunol 1995;154:772-779.
132. + T cells specificaly recognize a shared melanoma associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994;91:9461-9465.
133. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 1996;183:1965-1971.
134. + T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase. Cancer Res 1998;58:296-301.
135. 135. Kobayashi H, et al. Tyrosinase epitope recognized by an HLA DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient. Immunogenetics 1998;47:398-403.
136. 136. Halder T, et al. Isolation of novel HLA DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res 1997;57:3238-3244.
137. 137. Li K, et al. Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and annexin II eluted from melanoma cells. Cancer Immunol Immunother 1998;47:32-38.
138. + T lymphocytes. J Exp Med 1999;189:767-778.
139. + cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med 1999;189:871-876.
140. + T cells. J Exp Med 1999;189:757-766.
141. 141. Wang R-F, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumour antigen. Science 1999;284:1351-1354.
142. + T cells. J Exp Med 1999;189:1659-1667.
143. 143. Marchand M, et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995;63:883-885.
144. 144. Jager E, et al. Generation of cytotoxic T cell responses with synthetic melanoma-associated peptides in vivo: implication for tumor vaccines with melanoma-associated antigens. Int J Cancer 1996;66:162-169.
145. 145. Jager E, et al. Granulocyte-macrophage-colony stimulating factor enhances immune responses to melanoma associated peptides in vivo. Int J Cancer 1996;67:54-62.
146. 146. Cormier JN, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997;3:37-44.
147. 147. Parkhurst MR, et al. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A0201 binding residues. J Immunol 1996;157:2539-2548.
148. 148. Nestle FO, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332.
149. 149. Mukherji B, et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995;92:8078-8082.
150. 150. Hsu FJ, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-58.
151. 151. Marshall JL, et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 1999;17:332-336.